Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Assessing achievement and maintenance of glycemic control by patients initiating basal insulin.

Wu N, Aagren M, Boulanger L, Friedman M, Wilkey K.

Curr Med Res Opin. 2012 Oct;28(10):1647-56. doi: 10.1185/03007995.2012.722989. Epub 2012 Sep 2.

PMID:
22937724
4.

Are patients on basal insulin attaining glycemic targets? Characteristics and goal achievement of patients with type 2 diabetes mellitus treated with basal insulin and physician-perceived barriers to achieving glycemic targets.

Dalal MR, Grabner M, Bonine N, Stephenson JJ, DiGenio A, Bieszk N.

Diabetes Res Clin Pract. 2016 Nov;121:17-26. doi: 10.1016/j.diabres.2016.08.004. Epub 2016 Aug 24.

5.

Glycemic control with insulin glargine as part of an ethnically diverse, community-based diabetes management program.

Philis-Tsimikas A, Zhang Q, Walker C.

Am J Ther. 2006 Nov-Dec;13(6):466-72.

PMID:
17122525
6.

Glycemic control and long-acting insulin analog utilization in patients with type 2 diabetes.

Heintjes EM, Thomsen TL, Penning-van Beest FJ, Christensen TE, Herings RM.

Adv Ther. 2010 Apr;27(4):211-22. doi: 10.1007/s12325-010-0020-y. Epub 2010 May 4.

PMID:
20449697
7.

Evaluations of retinopathy in the VA Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM). A feasibility study.

Emanuele N, Klein R, Abraira C, Colwell J, Comstock J, Henderson WG, Levin S, Nuttall F, Sawin C, Silbert C, Lee HS, Johnson-Nagel N.

Diabetes Care. 1996 Dec;19(12):1375-81.

PMID:
8941467
8.

A comparison of insulin use, glycemic control, and health care costs with insulin detemir and insulin glargine in insulin-naive patients with type 2 diabetes.

Borah BJ, Darkow T, Bouchard J, Aagren M, Forma F, Alemayehu B.

Clin Ther. 2009 Mar;31(3):623-31. doi: 10.1016/j.clinthera.2009.03.005.

PMID:
19393853
9.

Outcomes associated with post-discharge insulin continuity in US patients with type 2 diabetes mellitus initiating insulin in the hospital.

Wu EQ, Zhou S, Yu A, Lu M, Sharma H, Gill J, Graf T.

Hosp Pract (1995). 2012 Oct;40(4):40-8. doi: 10.3810/hp.2012.10.1002.

PMID:
23299035
10.

Predictors for the initiation of a basal supported oral therapy (BOT) in type 2 diabetic patients under real-life conditions in Germany.

Kostev K, Dippel FW.

Prim Care Diabetes. 2012 Dec;6(4):329-35. doi: 10.1016/j.pcd.2012.06.001. Epub 2012 Jun 30.

PMID:
22749713
11.

Outcomes and treatment patterns of adding a third agent to 2 OADs in patients with type 2 diabetes.

Levin PA, Wei W, Zhou S, Xie L, Baser O.

J Manag Care Spec Pharm. 2014 May;20(5):501-12.

12.

Impact of time to treatment intensification on glycemic goal attainment among patients with type 2 diabetes failing metformin monotherapy.

Rajpathak SN, Rajgopalan S, Engel SS.

J Diabetes Complications. 2014 Nov-Dec;28(6):831-5. doi: 10.1016/j.jdiacomp.2014.06.004. Epub 2014 Jun 19.

PMID:
25104238
13.

Real-world comparative outcomes of US type 2 diabetes patients initiating analog basal insulin therapy.

Davis KL, Tangirala M, Meyers JL, Wei W.

Curr Med Res Opin. 2013 Sep;29(9):1083-91. doi: 10.1185/03007995.2013.811403. Epub 2013 Jun 21.

PMID:
23734906
14.

Glycemic control among patients with type 2 diabetes who initiate basal insulin: a retrospective cohort study.

Curtis B, Lage MJ.

J Med Econ. 2014 Jan;17(1):21-31. doi: 10.3111/13696998.2013.862538. Epub 2013 Nov 21.

PMID:
24195723
15.

Clinical and economic outcomes in patients with type 2 diabetes initiating insulin glargine disposable pen versus exenatide BID.

Baser O, Wei W, Baser E, Xie L.

J Med Econ. 2011;14(6):673-80. doi: 10.3111/13696998.2011.605818. Epub 2011 Sep 5.

PMID:
21892858
16.

Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM).

Abraira C, Henderson WG, Colwell JA, Nuttall FQ, Comstock JP, Emanuele NV, Levin SR, Sawin CT, Silbert CK.

Diabetes Care. 1998 Apr;21(4):574-9.

PMID:
9571345
17.

Time to insulin initiation and long-term effects of initiating insulin in people with type 2 diabetes mellitus: the Hoorn Diabetes Care System Cohort Study.

Mast R, Danielle Jansen AP, Walraven I, Rauh SP, van der Heijden AA, Heine RJ, Elders PJ, Dekker JM, Nijpels G, Hugtenburg JG.

Eur J Endocrinol. 2016 May;174(5):563-71. doi: 10.1530/EJE-15-1149. Epub 2016 Feb 2.

18.

Time to treatment initiation with oral antihyperglycaemic therapy in US patients with newly diagnosed type 2 diabetes.

Zhang Q, Rajagopalan S, Marrett E, Davies MJ, Radican L, Engel SS.

Diabetes Obes Metab. 2012 Feb;14(2):149-54. doi: 10.1111/j.1463-1326.2011.01498.x. Epub 2011 Oct 30.

PMID:
21952003
19.
20.

Starting insulin therapy with basal insulin analog or premix insulin analog in T2DM: a pooled analysis of treat-to-target trials.

Fonseca V, Davidson J, Home P, Snyder J, Jellinger P, Dyhr Toft A, Barnett A.

Curr Med Res Opin. 2010 Jul;26(7):1621-8. doi: 10.1185/03007995.2010.485087.

PMID:
20429817

Supplemental Content

Support Center